Abstract
In this work, the enhancement of drug dissolution rate through the preparation of new formulations containing Nimodipine in molecular level dispersion or in nanodispersion into poly(vinyl pyrrolidone) (PVP) matrix, was investigated. Differential scanning calorimetry (DSC) and modulated-temperature differential scanning calorimetry (MTDSC) in combination with X-ray powder diffractometry (XRPD) and scanning electron microscopy (SEM) studies showed that Nimodipine was amorphous in solid dispersions of 10 or 20 mass%, and mainly dispersed on a molecular level. This behaviour is attributed to the strong interactions taking place between the amine group of Nimodipine and carbonyl group of PVP. At higher drug loadings, crystal reflections in XRPD patterns and melting peaks of Nimodipine in DSC traces, indicated presence of drug in crystalline form. Micro-Raman studies in combination with SEM micrographs showed that the mean particle size increases with drug content in the formulations, up to 10 μm. Moreover, both XRPD patterns and micro-Raman spectra seem to indicate that Nimodipine crystallized in a second, thermodynamically stable, crystal modification II. The physicochemical characteristics of Nimodipine and the particle size distribution directly affect the dissolution rate enhancement, which is higher in amorphous dispersions.
Article PDF
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
References
H. Meyer, F. Bosset, W. Vater and K. Stoepel, US Patent, 3799934 (1983).
A. Grunenberg, A. Hegasy, W. Mück, G. Franckowiak and R. R Kanikanti, Bayer AG, DOS 4130173 (1992).
A. Grunenberg, B. Keil and J. O. Heck, Int. J. Pharm., 118 (1995) 11.
A. Grunenberg, J. O. Henck and H. W. Siesler, Int. J. Pharm., 129 (1996) 147.
Nimodipine Monograph, European Pharmacopoeia 4th Ed.
T. M. Cardoso, P. O. Rodrigues, H. K. Stulzer, M. A. S. Silva and J. R. Matos, Drug Dev. Ind. Pharm., 31 (2005) 631.
D. Hörter and J. B. Dressman, Adv. Drug Deliv. Rev., 56 (2001) 75.
C. Leuner and J. Dressman, Eur. J. Pharm. Biopharm., 50 (2000) 47.
D. Q. M. Craig, Int. J. Pharm., 231 (2002) 131.
J. L. Ford, Pharm. Acta Helv., 61 (1986) 69.
S. Verheyen, N. Blaton, R. Kinget and G. Van den Mooter, Int. J. Pharm., 249 (2002) 45.
H. Suzuki and H. Sunada, Chem. Pharm. Bull., 46 (1998) 1015.
E. Sjokvist-Saers, C. Nystrom and M. Alden, Int. J. Pharm., 90 (1993) 105.
A. T. M. Serajudin, J. Pharm. Sci., 88 (1999) 1058.
B. C. Hancock and G. Zografi, J. Pharm. Sci., 86 (1997) 1.
D. Q. M. Craig, Thermochim. Acta, 248 (1995) 189.
H. E. Junginger and M. Wedler, Pharm. Res., 3 (1986) 41.
L. S. Taylor and G. Zografi, Pharm. Res.,15 (1998) 755.
K. L. A. Chan and S. G. Kazarian, Mol. Pharm., 1 (2004) 331.
J. Breitenbach, W. Schrof and J. Neumann, Pharm. Res., 16 (1999) 1109.
T. R. M. De Beer, W. R. C. Baeyens, Y. V. Heyden, J. P. Remon, C. Vervaet and F. Verpooort, Eur. J. Pharm. Sci., 30 (2007) 229.
S. G. Skoulika and C. Georgiou, Appl. Specrosc., 55 (2001) 1259.
S. G. Skoulika and C. Georgiou, Appl. Specrosc., 57 (2003) 407.
G. Z. Papageorgiou, D. Bikiaris, E. Karavas, S. Politis, A. Docoslis, P. Yong, A. Stergiou and E. Georgarakis, The AAPS J., 8 (2006) E623.
G. Fini, J. Raman Spectrosc., 35 (2004) 335.
N. A. Urbanetz and B. H. Lippold, Eur. J. Pharm. Biopharm., 59 (2005) 107.
G. M. M. Babu, C. D. S. Prasad and K. V. R. Murthy, Int. J. Pharm., 234 (2002) 1.
K. P. Chowdary, K. V. R. Murthy and C. H. D. S. Prasad, Indian Drugs, 32 (1995) 537.
J. W. Lu, M. Z. Wang, P. Ding and Z. S. Pan, Chin. Pharm. J., 30 (1995) 23.
F. Kopecky, B. Kopecka, P. Kaclik and D. Struharova, Ceska a Slovenska Farmacie, 47 (1998) 233.
J. Cucala, A. Garcia, M. Montes and R. Obach, Proc. Int. Symp. Control. Release Bioact. Mater., 21 (1994) 720.
N. A. Urbanetz, Eur. J. Pharm. Sci., 28 (2006) 67.
B. Bikiaris, G. Z. Papageorgiou, A. Stergiou, E. Pavlidou, E. Karavas, F. Kanaze and M. Georgarakis, Thermochim. Acta, 439 (2005) 58.
E. Karavas, E. Georgarakis and D. Bikiaris, Int. J. Pharm., 313 (2006) 189.
F. I. Kanaze, E. Kokkalou, I. Niopas, M. Georgarakis, A. Stergiou and D. Bikiaris, J. Appl. Polym. Sci., 102 (2006) 460.
P. Gupta and A. K. Bansal, AAPS Pharm. Sci. Tech., 6 (2005) E223.
P. Gupta, R. Thilagavathi, A. K. Chakraborti and A. K. Bansal, Mol. Pharm., 2 (2005) 384.
S. D. Wang, L. G. Herbette and D. G. Rhodes, Acta Crystalogr., C45 (1989) 1748.
F. I. Kanaze, E. Kokkalou, I. Niopas, M. Georgarakis, A. Stergiou and D. Bikiaris, J. Therm. Anal. Cal., 83 (2006) 283.
E. Karavas, E. Georgarakis and D. Bikiaris, J. Therm. Anal. Cal., 84 (2006) 125.
B. Barbas, R. Prohens and C. Puigjianer, J. Therm. Anal. Cal., 89 (2007) 687.
D. Kiss, R. Zelkó, Cs. Novák and Zs. Éhen, J. Therm. Anal. Cal., 84 (2006) 447.
C. Mao, S. C. Prasanth, S. R. Byrn and R. Pinal, Pharm. Res., 23 (2006) 2269.
T. Miyazaki, S. Yoshioka and Y. Aso, Chem. Pharm. Bull., 54 (2006) 1207.
R. Kalaiselvan, G. P. Mohanta, P. K. Manna and R. Manavalan, Pharmazie, 61 (2006) 618.
H. Konno and L. S. Taylor, J. Pharm. Sci., 95 (2006) 2692.
G. Fox, Bull. Am. Phys. Soc., 1 (1956) 123.
M. Gordon and J. S. Taylor, J. Appl. Chem., 2 (1962) 493.
Z. H. Ping, Q. T. Nguyen and J. Néel, Makromol. Chem., 189 (1988) 437.
J. Prinos, D. Bikiaris and C. Panayiotou, Polymer, 40 (1999) 4741.
E. Karavas, E. Georgarakis and D. Bikiaris, Eur. J. Pharm. Biopharm., 64 (2006) 115.
E. Karavas, E. Georgarakis, M. P. Sigalas, K. Avgoustakis and D. Bikiaris, Eur. J. Pharm. Biopharm., 66 (2007) 334.
E. Karavas, E. Georgarakis, A. Docoslis and D. Bikiaris, Int. J. Pharm., 340 (2007) 76.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Papageorgiou, G.Z., Docoslis, A., Georgarakis, M. et al. The effect of physical state on the drug dissolution rate. J Therm Anal Calorim 95, 903–915 (2009). https://doi.org/10.1007/s10973-008-9225-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10973-008-9225-6